公开(公告)号：US20200250818A1

公开(公告)日：2020-08-06

申请号：US16756928

申请日：2018-10-29

Applicant: KOWA COMPANY, LTD.

Inventor： Katsumi Yabusaki

IPC: G06T7/00 ,  G06T7/62

Abstract: An analysis device includes: an acquirer that is configured to acquire data in which a physical quantity is associated with each unit area acquired by dividing a three-dimensional space, a three-dimensional time space, or a four-dimensional time space; a setter that is configured to set a detection region in a time space of three or more dimensions in the space or the time space and is configured to set a control region at a position surrounding a gap with the gap surrounding the detection region disposed in a space having the same dimensions as those of the detection region; and a determiner that is configured to determine whether or not one or more unit areas included in the detection region are predetermined areas on the basis of comparison between physical quantities of one or more unit areas included in the detection region and the control region set by the setter.

公开(公告)号：US20200222370A1

公开(公告)日：2020-07-16

申请号：US16627061

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Yuki KUROIWA ,  Akito MINAMIZONO

IPC: A61K31/423

Abstract: Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent storage stability. The pharmaceutical composition is provided to contain pemafibrate, a salt thereof or a solvate thereof, wherein a pH value of a solution produced by dissolving or dispersing the pharmaceutical composition in water is 7 or more.

公开(公告)号：US20200046686A1

公开(公告)日：2020-02-13

申请号：US16609249

申请日：2018-06-29

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi KOJIMA ,  Ryohei TANIGAWA

IPC: A61K31/423 ,  A61P1/16

Abstract: To provide an appropriate method of treatment with pemafibrate for a liver cirrhosis patient.The present invention relates to the use of pemafibrate in a liver cirrhosis patient.More particularly, the present invention relates to a regimen for administering a reduced dose of pemafibrate to a liver cirrhosis patient in need of treatment with pemafibrate than to persons with normal liver function.

公开(公告)号：US20200038397A1

公开(公告)日：2020-02-06

申请号：US16566473

申请日：2019-09-10

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki OHTA

IPC: A61K31/498 ,  A61P27/06 ,  A61K45/00 ,  A61K47/22 ,  A61K31/551

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)−)-1-(4-fluoro-S-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.

公开(公告)号：US10537579B2

公开(公告)日：2020-01-21

申请号：US15976135

申请日：2018-05-10

Applicant: JUNTENDO EDUCATIONAL FOUNDATION ,  KOWA COMPANY, LTD.

Inventor： Takenori Inomata ,  Toshinari Funaki

IPC: A61K31/551 ,  A61P27/02 ,  A61K9/08 ,  A61K9/00

Abstract: To provide a novel method for suppressing rejection after corneal transplantation.The method for suppressing rejection after corneal transplantation includes administering an effective amount of a Rho kinase inhibitor to a patient who needs it.

公开(公告)号：US20190342486A1

公开(公告)日：2019-11-07

申请号：US16474620

申请日：2018-01-30

Applicant: KOWA COMPANY, LTD.

Inventor： Tomohisa AZEGAMI

IPC: H04N5/232

Abstract: [Problem] To enable imaging to be performed with appropriate timing.[Solution] In a camera manipulation device 1 according to the present invention, a trigger signal T12 is issued and imaging is begun when a prescribed command is transmitted from a control circuit side to an imaging unit side (see S12). Because the issuance of such trigger signal T12 is not accepted before a character reception start command is issued, it is possible to perform imaging with appropriate timing.

公开(公告)号：US20190328509A1

公开(公告)日：2019-10-31

申请号：US16467473

申请日：2016-12-07

Applicant: Kowa Company, Ltd.

Inventor： Haruo ISHIKAWA

IPC: A61F2/16 ,  G02C7/04 ,  G02C7/02

Abstract: To realize a toric ophthalmic lens including an edge that makes it possible to design a lens contributing to secondary cataract prevention without deteriorating a degree of freedom of lens design. The toric ophthalmic lens is a toric ophthalmic lens in which, in a top view of an optical portion, a substantially flat portion having a substantially fixed edge thickness of the optical portion is provided to overlap a steep meridian of a toric surface of the optical portion.

公开(公告)号：US10413170B2

公开(公告)日：2019-09-17

申请号：US15107504

申请日：2014-12-22

Applicant: KOWA COMPANY, LTD.

Inventor： Satoshi Shimada ,  Takuya Hara

IPC: A61B3/024 ,  A61B3/00

Abstract: Through the present invention, a perimetry result is obtained for a position on a retina surface designated as a position to be tested. As illustrated in the drawing, “the position of a ganglion cell (RGC)” and “the position of a photoreceptor cell (C) for sending information to the ganglion cell (RGC)” are offset on the retina surface (macular part). Here, when position (P1) is designated as a test position for testing the functioning of a ganglion cell at position (P1), the perimeter of the present invention finds “the position (P2) of the photoreceptor cell for sending information to the ganglion cell at position (P1),” presents a visual target at position (P2) rather than position (P1), and tests a visual field. The information of the visual target is sent to the ganglion cell at position (P1), and the functioning of the ganglion cell can therefore be tested. The test result is correlated with the position (P1) and displayed, and the ganglion cell at the designated position (P1) can be therefore be tested.

公开(公告)号：US20190258075A1

公开(公告)日：2019-08-22

申请号：US16374849

申请日：2019-04-04

Applicant: KOWA COMPANY, LTD.

Inventor： Hirofumi YAGI

IPC: G02B27/64 ,  H04N5/232 ,  H04N5/225 ,  G03B17/14 ,  G02B7/02 ,  G03B9/02 ,  G03B15/00

Abstract: A lens barrel detachably attached to a camera body includes a fixed tube section that has a base end installed at the camera body, and a top end, a first pitch screw section being formed on an inner peripheral surface of the top end; a movable tube section that is a tube member configured to hold a plurality of lens and has a second pitch screw section on the movable tube side formed at an outer peripheral surface, and is located so as to be movable inside the fixed tube section in such a state that the second pitch screw section is threadedly engaged with the first pitch screw section, the plurality of lens including two group of lenses, a first group and a second group, held within the movable tube section. The movable tube section having a fixed diaphragm plate that is detachable.

公开(公告)号：US10376523B2

公开(公告)日：2019-08-13

申请号：US15514259

申请日：2015-09-25

Applicant: KOWA COMPANY, LTD.

Inventor： Shin Sugimoto

IPC: A61K31/551 ,  A61K47/18 ,  A61K9/08 ,  A61P27/02 ,  A61K9/00 ,  A61K31/435 ,  A61K33/42

Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition containing: a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof, where X represents a halogen atom, and a quaternary ammonium surfactant. A method for producing an aqueous composition with an antiseptic effect, by incorporating a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof and a quaternary ammonium surfactant into the aqueous composition.